In addition, we demonstrated that AZD2281 induces growth inhibition in BRCA wild-type breast cancer cell lines with BRCA1 allelic loss, indicating that breast cancer patients with BRCA1 allelic loss may benefit from PARP inhibitors. This evidence concerns the gene BRCA1 and breast cancer.